BRPI0407300A - Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas - Google Patents
Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativasInfo
- Publication number
- BRPI0407300A BRPI0407300A BR0407300-2A BRPI0407300A BRPI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A
- Authority
- BR
- Brazil
- Prior art keywords
- hsgk1
- hsgk3
- gene
- protein
- nucleic acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940121649 protein inhibitor Drugs 0.000 title abstract 2
- 239000012268 protein inhibitor Substances 0.000 title abstract 2
- 238000012216 screening Methods 0.000 title abstract 2
- 238000013518 transcription Methods 0.000 title abstract 2
- 230000035897 transcription Effects 0.000 title abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 108700026220 vif Genes Proteins 0.000 title 1
- 208000002177 Cataract Diseases 0.000 abstract 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 4
- 208000010412 Glaucoma Diseases 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/166—Cataract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305212A DE10305212A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| PCT/EP2004/001048 WO2004069258A2 (de) | 2003-02-07 | 2004-02-05 | Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407300A true BRPI0407300A (pt) | 2006-02-07 |
Family
ID=32730900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0407300-2A BRPI0407300A (pt) | 2003-02-07 | 2004-02-05 | Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1663246A2 (enExample) |
| JP (1) | JP2006519189A (enExample) |
| KR (1) | KR20050114214A (enExample) |
| CN (1) | CN1771039A (enExample) |
| AU (1) | AU2004210416A1 (enExample) |
| BR (1) | BRPI0407300A (enExample) |
| CA (1) | CA2514703A1 (enExample) |
| DE (1) | DE10305212A1 (enExample) |
| MX (1) | MXPA05008394A (enExample) |
| PL (1) | PL378399A1 (enExample) |
| RU (1) | RU2005127808A (enExample) |
| WO (1) | WO2004069258A2 (enExample) |
| ZA (1) | ZA200506280B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005229497A1 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for interfering with fibrosis |
| WO2005094829A1 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
| DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
| US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
| WO2007037560A1 (ja) * | 2005-09-30 | 2007-04-05 | Link Genomics, Inc. | Ｓｇｋ２遺伝子の治療的又は診断的用途 |
| WO2007062101A2 (en) * | 2005-11-22 | 2007-05-31 | Mcgill University | Intraocular pressure-regulated early genes and uses thereof |
| US20080153903A1 (en) * | 2006-12-22 | 2008-06-26 | Alcon Manufacturing, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| US9012161B2 (en) * | 2011-01-25 | 2015-04-21 | Monell Chemical Senses Center | Methods of identifying molecules that provide or enhance sweet taste |
| KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
| CN119303113A (zh) * | 2024-09-03 | 2025-01-14 | 河北大学附属医院 | Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996006863A1 (en) * | 1994-08-30 | 1996-03-07 | University Of Dundee | Agents for inducing apoptosis and applications of said agents in therapy |
| EP0832295A1 (en) * | 1995-06-07 | 1998-04-01 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists and antagonists |
| US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
| AU3991499A (en) * | 1998-05-15 | 1999-12-06 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
| DE69937159T2 (de) * | 1998-12-14 | 2008-06-26 | University Of Dundee, Dundee | Verfahren zur Aktivierung von SGK durch Phosphorylierung. |
| US6399655B1 (en) * | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| WO2001004145A2 (en) * | 1999-07-14 | 2001-01-18 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
| US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
| US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305212A patent/DE10305212A1/de not_active Withdrawn
-
2004
- 2004-02-05 WO PCT/EP2004/001048 patent/WO2004069258A2/de not_active Ceased
- 2004-02-05 MX MXPA05008394A patent/MXPA05008394A/es unknown
- 2004-02-05 CN CNA2004800070348A patent/CN1771039A/zh active Pending
- 2004-02-05 EP EP04708350A patent/EP1663246A2/de not_active Withdrawn
- 2004-02-05 CA CA002514703A patent/CA2514703A1/en not_active Abandoned
- 2004-02-05 RU RU2005127808/15A patent/RU2005127808A/ru not_active Application Discontinuation
- 2004-02-05 KR KR1020057014582A patent/KR20050114214A/ko not_active Withdrawn
- 2004-02-05 PL PL378399A patent/PL378399A1/pl not_active Application Discontinuation
- 2004-02-05 JP JP2006501737A patent/JP2006519189A/ja active Pending
- 2004-02-05 BR BR0407300-2A patent/BRPI0407300A/pt not_active IP Right Cessation
- 2004-02-05 AU AU2004210416A patent/AU2004210416A1/en not_active Abandoned
-
2005
- 2005-08-05 ZA ZA200506280A patent/ZA200506280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL378399A1 (pl) | 2006-04-03 |
| RU2005127808A (ru) | 2006-05-27 |
| MXPA05008394A (es) | 2005-10-05 |
| WO2004069258A3 (de) | 2005-02-24 |
| CN1771039A (zh) | 2006-05-10 |
| JP2006519189A (ja) | 2006-08-24 |
| EP1663246A2 (de) | 2006-06-07 |
| ZA200506280B (en) | 2006-05-31 |
| KR20050114214A (ko) | 2005-12-05 |
| AU2004210416A1 (en) | 2004-08-19 |
| CA2514703A1 (en) | 2004-08-19 |
| DE10305212A1 (de) | 2004-08-19 |
| WO2004069258A2 (de) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tanaka et al. | Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system | |
| Cramer et al. | Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease | |
| Pieragostino et al. | Shotgun proteomics reveals specific modulated protein patterns in tears of patients with primary open angle glaucoma naive to therapy | |
| Garweg et al. | Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma | |
| Igarashi et al. | Aqueous autotaxin and TGF-βs are promising diagnostic biomarkers for distinguishing open-angle glaucoma subtypes | |
| EP2558862B1 (en) | Diagnostic methods for glaucoma | |
| US20190085394A1 (en) | Refining diagnosis and treatment of complex multi-symptom neurological disorders | |
| WO2015153864A2 (en) | Methods for treating inflammatory conditions | |
| BRPI0407300A (pt) | Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas | |
| Rasmussen et al. | Impulsivity in hoarding | |
| Lynch et al. | Plasma biomarkers of reticular pseudodrusen and the risk of progression to advanced age-related macular degeneration | |
| Garweg et al. | Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment | |
| Gerace et al. | The gliadin peptide 31-43 exacerbates kainate neurotoxicity in epilepsy models | |
| Khawaja et al. | Potential for collider bias in studies examining the association of central corneal thickness with glaucoma | |
| US20150301049A1 (en) | Method for diagnosing and treating kidney injury or disease | |
| KR102411176B1 (ko) | Slc4a5를 포함하는 난청 진단용 바이오마커 조성물 및 이의 용도 | |
| Bharwani et al. | Serum Soluble Interleukin‐2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting | |
| WO2017175181A1 (en) | Angiogenin as a diagnostic or prognostic biomarker and drug target in age-related macular degeneration | |
| DE502004012230D1 (de) | Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i | |
| Sahajpal et al. | Deranged metabolic profile and identification of biomarkers in the vitreous humour of patients with proliferative diabetic retinopathy | |
| Picciani et al. | Potential for transcriptional upregulation of cochlin in glaucomatous trabecular meshwork: a combinatorial bioinformatic and biochemical analytical approach | |
| US20240036064A1 (en) | Methods and compositions for detecting cognitive disorder | |
| Lozano et al. | Profiling IOP-responsive genes in anterior and posterior ocular tissues in the rat CEI glaucoma model | |
| Wijesundara et al. | Comparison of serum oxidative stress, antioxidant parameters and vitamin D levels of Sri Lankan patients with multiple sclerosis and neuromyelitis optica: A pilot study | |
| Chelune et al. | Application of reliable change methods for identifying abnormal rates of cognitive decline in dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |